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Introduction: Interleukin-8 is thought to play a role in neutrophil activation
and transcapillary migration into the interstitium. Because neutrophils are
principal effector cells in acute myocardial ischemia-reperfusion injury, we
postulated that the inhibition of interleukin-8 activity with a neutralizing
monoclonal antibody directed against rabbit interleukin-8 (ARIL8.2) would
attenuate the degree of myocardial injury encountered during reperfusion.
Methods: In New Zealand White rabbits, the large branch of the marginal
coronary artery supplying most of the left ventricle was occluded for 45
minutes, followed by 2 hours of reperfusion. Fifteen minutes before
reperfusion, animals were given an intravenous bolus of either 2 mg/kg of
ARIL8.2 or 2 mg/kg anti–glycoprotein-120, an isotype control antibody that
does not recognize interleukin-8. At the completion of the 120-minute
reperfusion period, infarct size was determined. Results: In the area at risk
for infarction, 44.3% 6 4% of the myocardium was infarcted in the
anti–glycoprotein-120 group compared with 24.8% 6 9% in the ARIL8.2
group (p < 0.005). In control animals, edema and diffuse infiltration of
neutrophils were observed predominantly in the infarct zone and the
surrounding area at risk. Tissue myeloperoxidase determinations did not
differ significantly between groups, indicating that the cardioprotective
effect of ARIL8.2 was independent of an effect on neutrophil infiltration.
Conclusions: A specific monoclonal antibody that neutralizes interleukin-8
significantly reduces the degree of necrosis in a rabbit model of myocardial
ischemia-reperfusion injury. (J Thorac Cardiovasc Surg 1998;116:114-21)
Myocardial ischemia-reperfusion injury is a majordeterminant of morbidity and mortality in pa-
tients undergoing cardiothoracic operations. De-
spite the use of such cardioprotective techniques as
cardioplegia and hypothermia, a significant degree
of cardiac dysfunction is encountered during and
after the operation, particularly in patients who
sustained significant physiologic deterioration be-
fore the operation.1, 2 Several pathogenic mecha-
nisms involving the activated endothelium mediate
this distinct form of tissue injury. Numerous studies
show that neutrophils accumulate rapidly in and
around the infarcted tissue after reperfusion.3, 4 In
the process of adhering to the endothelium, neutro-
phils become activated. Activated leukocytes medi-
ate tissue injury through the release of a variety of
substances, such as oxygen-derived free radicals and
proteases, that are involved in necrotic tissue re-
modeling.5 Adjacent tissue that is still viable may
also be damaged irreversibly by these neutrophil
products, resulting in extension of the infarct size.
Evidence supporting the importance of neutro-
phils in ischemia-reperfusion injury is provided by
studies with monoclonal antibodies against adhesion
molecules, which block many of the deleterious
effects of reperfusion of ischemic tissue (see refer-
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ence 1 for review). Neutrophil-mediated injury dur-
ing reperfusion results when flowing neutrophils
encounter activated endothelial cells expressing ad-
hesion molecules that mediate an initial rolling and
then firm adherence. During this process the neu-
trophils become activated, promoting chemotaxis
into the ischemic tissue.6-8 A variety of chemotactic
factors contribute to neutrophil activation and che-
motactic function. It is conceivable that by inhibiting
one of the factors that promote activation or che-
motaxis it may be possible to attenuate myocardial
ischemia-reperfusion injury without globally affect-
ing neutrophil-endothelial cell adhesion.
The chemokine interleukin 8 (IL-8) was recently
shown in vitro to be an important mediator of
neutrophil activation and transendothelial migra-
tion.9 Reoxygenation of cultured hypoxic endothe-
lial cells and monocytes induces the release of
significantly elevated quantities of IL-8.10, 11 Recent
evidence suggests a role for IL-8 in the injury
pattern seen after myocardial infarction and cardio-
pulmonary bypass. Elevated IL-8 levels are detected
in the serum of patients after myocardial infarction,
and IL-8 is measured in coronary sinus blood after
ischemic cardiac arrest during heart operations re-
quiring cardiopulmonary bypass.12, 13 Because the
activation of neutrophils is a known prominent
feature of myocardial ischemia-reperfusion injury,
we postulated that the inhibition of IL-8 activity with
a monoclonal antibody capable of neutralizing IL-8
would attenuate the degree of myocardial injury
encountered during reperfusion.
Methods
Monoclonal antibody. A neutralizing antirabbit IL-8
antibody (ARIL8.2) was generated and screened for
specificity as described elsewhere in detail.14, 15 This an-
tibody was selected from a series of antirabbit IL-8
monoclonal antibodies because of its demonstrated ability
to bind recombinant rabbit IL-8, inhibit rabbit IL-8 bind-
ing to rabbit neutrophils, and finally, to prevent IL-8
mediated neutrophilic chemotaxis and degranulation.14, 15
A matching idiotypic antibody (anti–gp-120), one that
binds the major envelope glycoprotein of human immu-
nodeficiency virus type 1, glycoprotein-120, but does not
bind rabbit IL-8, was used as a control.
In situ coronary ligation model. To evaluate the effect
of inhibiting IL-8 on injury sustained during ischemia-
reperfusion, we used a well-characterized regional isch-
emia-reperfusion injury model. In this model adult New
Zealand White rabbits weighing 3 to 4 kg were used in
research protocols approved by the Animal Care Commit-
tee of the University of Washington, Seattle. All animals
received humane care according to the “Guide for the
Care and Use of Laboratory Animals” prepared by the
Institute of Laboratory Animal Resources and published
by the National Institutes of Health (NIH Publication No.
86-23, revised 1985). Rabbits were anesthetized with an
initial intramuscular injection of ketamine (35 mg/kg) and
xylazine (5 mg/kg). The rabbits were endotracheally intu-
bated and maintained on inhaled halothane (1% to 2%)
anesthesia in 100% oxygen administered with a small-
animal respirator. A 20-gauge flexible catheter was placed
in the left carotid artery to measure heart rate (HR),
measure mean arterial pressure (MAP), and collect blood
samples. A double-lumen thermodilution probe and injec-
tate catheter (model 94-011-3F; Baxter Healthcare Cor-
poration, Irvine, Calif.) were placed retrograde through
the left femoral artery and vein to the aorta and inferior
vena cava to measure core temperature and cardiac
output (CO) by thermodilution technique. The heart was
exposed through a median sternotomy. A 5F Millar
catheter was placed through a small purse-string sutured
incision in the left ventricle to allow estimation of the left
ventricular peak systolic pressure (LVESP) and left ven-
tricular end-diastolic pressure (LVEDP). A 4.0 Vicryl
suture (Ethicon, Inc., Somerville, N.J.) was passed twice
around a large arteriolateral branch of the left main
coronary artery supplying most of the left ventricle, and
the ends of the suture were passed through a small length
of polyethylene tubing to form a snare. After a 20- to
30-minute stabilization period, baseline values were re-
corded. Regional myocardial ischemia was produced by
reversibly occluding the artery for 45 minutes, followed by
120 minutes of reperfusion. Fifteen minutes before reper-
fusion, animals were given intravenously 2 mg/kg anti–gp-
120 (the nonbinding control antibody) or 2 mg/kg
ARIL8.2. Thermodilution CO, central venous pressure
(CVP), HR, MAP, LVESP, and LVEDP were recorded at
baseline, 45 minutes of ischemia, and 60 and 120 minutes
of reperfusion. The CO determinations were performed in
triplicate and the results were averaged. Systemic vascular
resistance was calculated as (MAP 2 CVP) 3 80/CO 3
(dynes z sec z cm–5). Additional mechanical hemodynamic
data calculated during this preparation included maxi-
mum positive pressure change, pressure rate index
(LVESP 3 HR/1000), and developed pressure (LVESP 2
LVEDP). After 120 minutes of reperfusion, all animals
were killed with an intravenous bolus of concentrated
pentobarbital and the myocardial tissue was taken and
processed for calculation of infarct size or histologic
analysis.
Determination of infarct size. At completion of the
120-minute reperfusion period, the coronary artery was
reoccluded and 6 ml 20% Evans blue dye (Sigma Chem-
ical Co., St. Louis, Mo.) was injected into the left atrium
and allowed to circulate to stain all perfused tissue. The
area supplied by the ligated vessel remained unstained,
demarcating the myocardium at risk for infarction. After
the heart was arrested with pentobarbital, it was rapidly
excised. The left ventricle was isolated from the rest of the
heart, weighed, and then cut into 2 mm thick transverse
slices. The normal myocardium (stained blue) was sepa-
rated from the area at risk (unstained). The area at risk
was placed in a 37° C solution of 1% triphenyltetrazolium
chloride (TTC) for 30 minutes. TTC stains the viable
tissue brick red, leaving the necrotic zone pale. The
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TTC-stained (noninfarcted) tissue was separated from the
TTC-unstained (necrotic) tissue and each area was
weighed. The left ventricular area at risk (LVAAR) was
calculated as the sum of the noninfarcted and necrotic
weights of the tissue perfused by the occluded vessel
divided by the weight of the left ventricle, expressed as a
percentage. The left ventricular area of necrosis (LVAN)
was calculated as the weight of necrotic tissue divided by
the weight of the left ventricle, expressed as a percentage.
The infarct size was calculated by dividing the weight of
the TTC-unstained tissue by the weight of the total area at
risk (LVAN/LVAAR).
Myeloperoxidase (MPO) assay. Tissue neutrophil ac-
cumulation was quantified by MPO assay. Left ventricular
area not at risk and LVAAR were isolated as described
previously; however, the LVAN was not separated out
from the LVAAR. These tissues were homogenized in a
solution containing 20 mmol/L potassium phosphate and
centrifuged for 30 minutes at 20,000g at 4° C. The pellets
were frozen on dry ice overnight. After thawing, the
pellets were sonicated for 1 minute at 4° C in a buffer
solution consisting of 0.5% hexylcyclotrimethylammo-
nium bromide dissolved in 50 mmol/L potassium phos-
phate buffer (pH 6) containing 30 U/ml aprotinin. The
samples were centrifuged for 30 minutes at 40,000g at
4° C. An aliquot of the supernatant was allowed to react
with a solution of o-inosidine dihydrochloride. Activity
was defined as the quantity of enzyme degrading 1 mmol
peroxide/min at 37° C and expressed in units per gram
weight of tissue.
Microvascular blood flow. Regional myocardial blood
flow was measured in 11 additional rabbits. Colored (high
red, medium red, blue, and violet) polystyrene micro-
spheres (15 6 0.1 mm in diameter; Triton Technology,
San Diego, Calif.) were used to measure flow at baseline,
end of ischemia, and 1 and 2 hours after reperfusion,
according to previously described methods.16 Approxi-
mately 500,000 microspheres were suspended in 1 ml
normal saline solution and then injected through a cath-
eter positioned in the left ventricle. Withdrawal of refer-
ence arterial blood flow was begun through a catheter
placed in the carotid artery 30 seconds before micro-
sphere injection and continued for 30 seconds after the
injection. To distinguish the normally perfused myocar-
dium from the myocardium that was made ischemic by the
coronary occlusion, the coronary artery was again ligated
immediately after the last microsphere injection, and the
animals received 5 ml 10% Evans blue dye, as described
previously. Nonischemic tissue from the right ventricle
and ischemic tissue from the left ventricle were easily
identified and separated by this technique. The micro-
spheres were then recovered from the tissue and blood
samples by digestion in a 4 mol/L potassium hydroxide
solution at 72° C for 3 hours and subsequent microfiltra-
tion. The dyes were recovered from the spheres within a
known volume of a solvent (dimethylformamide) and
their concentrations were determined by spectrophotom-
etry at the optimal wavelengths for each dye. The com-
posite spectrum of each dye solution was resolved into the
spectra of the single constituents by a matrix inversion
technique. Blood flow to each myocardial sample was
calculated by determining total tissue spheres divided by
the tissue weight in grams. This value was then multiplied
by the inverse of the spheres per milliliter per minute
(total references spheres divided by withdrawal rate).
Statistics. Student’s t tests were used to compare the
mean percentage changes in infarct size and MPO levels
between the ARIL8.2 and anti–gp-120 groups. Hemody-
namic and microvascular blood flow parameters were
compared with baseline values by means of paired t tests
and between treatment groups by means of independent
sample t tests at each time point.
Results
Forty-six animals treated with either the ARIL8.2
or anti–gp-120 antibody were included in this anal-
ysis. Eleven animals were used to determine infarct
size, 20 were examined to assess MPO activity, 10
were used to assess myocardial blood flow at the
microvascular level, and five were examined by
fixation of tissue and hematoxylin-eosin staining.
Three were excluded because of ventricular fibrilla-
tion during early ischemia, before antibody infusion.
One ARIL8.2-treated animal had intermittent fibril-
lation during the 45-minute ischemic period and was
excluded when it died of refractory fibrillation im-
mediately on reperfusion. One anti–gp-120–treated
animal was excluded for refractory ventricular fibril-
lation at 1 hour of reperfusion.
Effect of ARIL8.2 on myocardial infarct size.
Ligation of the proximal marginal artery in the
rabbit heart consistently created equivalent
LVAARs in the two groups (Fig. 1). In the anti–gp-
120–treated animals, LVAAR was 43% 6 5% (n 5
5), compared with 49% 6 2% in the ARIL8.2-
Fig. 1. LVAAR and infarct size, expressed as a percent-
age of LVAAR divided by LVAN. Values are expressed
as mean 6 standard error of the mean.
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treated animals (n 5 6). This difference was not
statistically significant. Of the LVAAR, 44.3% 6
2% was infarcted in the anti–gp-120–treated group,
compared with 24.8% 6 4% in the ARIL8.2 group
(Fig. 1). This represents a 56% reduction in infarct
size in the ARIL8.2-treated animals compared with
the control group (p # 0.001).
MPO assay. MPO contents of the nonischemic
left ventricle and LVAAR were compared between
animals treated with ARIL8.2 (n 5 10) and anti–
gp-120 (n 5 10) (Fig. 2). There was no statistically
significant difference in MPO activity between the
areas not at risk for infarction in the ARIL8.2-
treated and anti–gp-120–treated animals (1.4 6
0.18 U/gm vs 1.3 6 0.16 U/gm; p 5 0.84). Further-
more, the difference in MPO levels between the
ARIL8.2-treated and anti–gp-120–treated animals
was not statistically significant (2.2 6 0.32 vs 2.3 6
0.54; p 5 0.104).
Regional microvascular blood flow. The time
course of regional myocardial blood flow, expressed
as a percentage reduction from baseline, is shown in
Fig. 3. In both anti–gp-120–treated (n 5 4) and
ARIL8.2-treated animals (n 5 6), blood flow was
significantly reduced from baseline levels in the
LVAAR during ischemia (12% 6 2% vs 20% 6 6%
of baseline). Blood flow recovered to 76% 6 25% of
baseline in the ARIL8.2-treated animals, compared
with 83% 6 21% in anti–gp-120–treated animals at
60 minutes of reperfusion. By 120 minutes of reper-
fusion, there was still no significant difference be-
tween the recovery to baseline in the ARIL8.2-
treated animals (62% 6 18%) and the anti–gp-120–
treated animals (89% 6 11%). In both groups,
myocardial blood flow was reduced with respect to
baseline at 60 and 120 minutes of reperfusion; there
was no significant difference between treatment
groups.
Effect of ARIL8.2 on hemodynamics. MAP, CO,
LVESP, and developed pressure were all signifi-
cantly reduced at the end of ischemia in both
groups. Although there were some trends toward
improved recovery in the ARIL8.2-treated animals,
there were no significant changes in measured
global myocardial function in any of these parame-
ters between treatment groups at any time point
(Table I).
Discussion
Recent experimental and clinical observations
have implicated IL-8 in myocardial ischemia-reper-
fusion injury. In a canine model of myocardial
ischemia-reperfusion injury, IL-8–specific messen-
ger ribonucleic acid is markedly elevated in reper-
fused segments of myocardium and is limited to
both viable and necrotic tissue around the infarct
Fig. 2. MPO activity in the left ventricle area not at risk
for infarction versus LVAAR in anti–gp-120–treated
versus ARIL8.2-treated animals. Data are expressed as
mean 6 standard error of the mean of units of MPO
activity per gram of tissue. There was no statistical differ-
ence between the anti–gp-120–treated and ARIL8.2-
treated animals in left ventricle area not at risk or
LVAAR, suggesting that the reduction in infarct size was
not caused by attenuation of the degree of neutrophil
infiltration into the LVAAR.
Fig. 3. Microvascular blood flow in the LVAAR in
ARIL8.2-treated animals versus anti–gp-120–treated an-
imals. Blood flow at baseline, the end of ischemia, and
after 1 and 2 hours of reperfusion is expressed in millili-
ters per minute per gram, as determined by colored
microsphere technique. Mean 6 standard error of the
mean is shown at each time point.
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zone.17 Clinically, a correlation between serum IL-8
levels and transmural acute myocardial infarction is
observed,12 and atrial IL-8 messenger ribonucleic
acid levels increase by several times during cardio-
pulmonary bypass after ischemic arrest of the
heart.18 In addition, elevated IL-8 levels correlate
with the length of cardiopulmonary bypass and
coronary sinus myoglobin level, a biochemical
marker of myocyte injury.13, 19 These studies suggest
a correlation between IL-8 expression and myocar-
dial injury from oxidative stress. The role of IL-8 as
a contributing factor in myocardial ischemia-reper-
fusion injury, however, was not previously known.
In this study we found that intravenous adminis-
tration of a monoclonal antibody to IL-8 reduces
regional myocardial ischemia-reperfusion injury.
This study provides the first evidence that inhibition
of IL-8 prevents the extension of myocardial infarc-
tion on reperfusion. The protective mechanism of
neutralizing IL-8 appears to involve inhibition of
neutrophil activation in the secondary zone of at-
risk ischemic myocardium, the area most vulnerable
to oxidative injury and further tissue necrosis during
reperfusion. Although inhibition of IL-8 during re-
gional myocardial ischemia-reperfusion injury re-
duced the extent of infarction, a trend toward
improved ventricular performance in ARIL8.2-
treated animals compared with anti–gp-120–treated
animals, as assessed by measurements of ventricular
contractility, did not reach statistical significance
(Table I). Conclusions about ventricular function
are limited in this initial study, however, because
with this model only a small fraction of the ventricle
is infarcted and otherwise healthy rabbits are able to
compensate hemodynamically for this degree of
injury. Further studies in which regional myocardial
function is more specifically studied or in which the
heart is subjected to global ischemic injury will more
specifically assess the effect of the ARIL8.2 antibody
on recovery of ventricular function.
IL-8 plays an important role in both neutrophil
activation and chemotaxis. In studies in which IL-8
alone was injected into normal human skin, neutro-
phils were recruited without the appearance of
wheal or flare, suggesting that IL-8 works in coop-
eration with other inflammatory mediators.20 Van
Zee and colleagues21 demonstrated that a single-
dose infusion of plasma concentrations seen in
sepsis of recombinant IL-8 into nonhuman primates
resulted in a rapid margination of neutrophils in the
lungs and other systemic tissue beds; however, se-
vere neutrophil-mediated injury did not result. In
contrast, when IL-8 is neutralized in the presence of
severe tissue injury, where other inflammatory me-
diators are present, a significant degree of injury is
averted.14, 15 These observations suggest that IL-8
works with other inflammatory mediators and that
its primary role is in neutrophil activation and
chemotaxis.
Our results corroborate previous studies demon-
strating that inhibition of neutrophil function is
cardioprotective in myocardial ischemia-reperfusion
injury. Monoclonal antibodies, peptides, or small
molecules such as oligosaccharides that either bind
the adhesion molecule directly or interfere with the
molecule binding to its ligand have been effective in
limiting myocardial injury on reperfusion. For exam-
ple monoclonal antibodies to P-selectins and L-
selectins, CD11a, CD11b, CD18, and intercellular
adhesion molecule–1 have all been shown to atten-
uate myocardial ischemia-reperfusion injury (for a
review, see reference 1). Therapies that inhibit
Table I. Hemodynamic values in ARIL8.2-treated animals and anti-GP120-treated animals
Time 0 Time 45 min Time 120 min
Anti–GP-20 ARIL8.2 Anti–GP-120 ARIL8.2 Anti–GP-120 ARIL8.2
HR 100 6 0 100 6 0 107 6 8 96 6 4.9 97 6 6.2 101 6 8
MAP 100 6 0 100 6 0 73 6 4.4 79 6 6.1 74 6 6.7 77 6 8.6
CO 100 6 0 100 6 0 69 6 8.8 72 6 4.7 75 6 9.3 75 6 5.5
CVP 100 6 0 100 6 0 97 6 3.2 103 6 6.6 94 6 3.4 108 6 4.9
SVR 100 6 0 100 6 0 114 6 19 108 6 5.8 98 6 3.2 99 6 7.4
dP/dt 100 6 0 100 6 0 76 6 4.2 79 6 1.9 68 6 9.1 81 6 5.1
LVESP 100 6 0 100 6 0 90 6 12 83 6 5.5 80 6 4.4 85 6 5.5
LVEDP 100 6 0 100 6 0 510 6 187 191 6 31 375 6 114 159 6 29
DP 100 6 0 100 6 0 73 6 2.9 77 6 5.7 75 6 5.2 80 6 5
PRI 100 6 0 100 6 0 86 6 9.7 81 6 9.5 78 6 9.3 88 6 12
All values are expressed as a percentage of baseline value, plus or minus the standard error of the mean. SVR, systemic vascular resistance; 1dP/dt, maximum
positive pressure charge; DP, developed pressure; PRI, pressure rate index.
The Journal of Thoracic and
Cardiovascular Surgery
July 1998
1 1 8 Boyle et al.
neutrophil adherence to endothelium, however, may
carry the potential risk of infectious complications.22
This may be especially true in clinical situations in
which the risk of infection is great. In contrast,
neutralizing IL-8 does not directly block neutrophil-
endothelial adhesive properties or responsiveness to
other neutrophil chemotactic factors, such as plate-
let-activating factor, complement 5a, or leukotriene
B4. The premise that IL-8 inhibition does not se-
verely suppress nonspecific immunity is supported
by studies with IL-8 receptor homolog knockout
mice. These animals do not appear to have severe
bacterial infections, despite an impairment in ex-
travascular neutrophil recruitment to such stimuli as
endotoxin.23 Approaches that are based on an anti-
body to IL-8 may be a useful adjunct when infec-
tious risks are high or there are other contraindica-
tions to anti–neutrophil-adhesion therapy.
Although ARIL8.2 significantly reduced infarct
size in our model, neutrophil accumulation in reper-
fused tissue, as measured by MPO, was not appre-
ciably reduced by the antibody. IL-8 is both a
leukocyte chemoattractant and a potent agent of
leukocyte activation, and it is one of a number of
chemoattractants that may be activated in response
to reperfusion injury. It is possible that other che-
moattractants (for example, complement fragment
5a), which would not be affected by ARIL8.2, were
generated in our model of myocardial ischemia-
reperfusion injury, causing neutrophils to migrate to
sites of reperfused tissue. We conjecture that in the
presence of ARIL8.2 these leukocytes were not
activated and did not release granular contents that
damage tissue.24 Our results thus suggest that IL-8
plays a more important role in ischemia-reperfusion
injury as a neutrophil-activating agent than as a
chemoattractant.
This study suggests potentially clinical beneficial
effects of inhibiting IL-8 in the setting of myocardial
ischemia-reperfusion injury. This conclusion has
ramifications for the treatment of the reperfused
myocardium in a variety of clinical settings, includ-
ing the treatment of areas of potentially salvageable
myocardium in patients after acute myocardial in-
farction or as an adjunct to current myocardial
protection strategies in the setting of cardiopulmo-
nary bypass and heart transplantation. In addition,
there is evidence that IL-8 may contribute to inflam-
matory-mediated pulmonary injury as well. In sev-
eral models of severe lung injury, the neutralization
of IL-8 (with ARIL8.2) has been shown to pro-
foundly inhibit neutrophil recruitment and subse-
quent neutrophil-mediated lung injury.14, 15 Treat-
ing patients undergoing cardiopulmonary bypass
with an agent to neutralize IL-8 therefore not only
could have an impact on the degree of myocardial
injury but could also reduce some of the whole-body
inflammatory response that contributes significantly
to morbidity and mortality among patients undergo-
ing heart operations.
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Discussion
Dr. David A. Fullerton (Winnetka, Ill.). Dr. Boyle, you
and your colleagues are to be sincerely complimented on
a rigorous progression of studies trying to iron out some of
the mechanisms of ischemia and reperfusion injuries. I
know the focus of your laboratory has been on endothelial
cell function and interaction with leukocytes, and this is
one more step along that path. Most of us do not think
much about IL-8—or any other cytokines—on a daily
basis, and your presentation was clear.
Having seen some of the IL-8 work that you presented
in your background in the literature recently, I viewed it as
interesting, but most other cytokines are also elevated
when a person is undergoing cardiopulmonary bypass.
What prompted you to focus on the role of IL-8 in
neutrophil–endothelial cell interaction? Do you believe
that this is early enough in the cascade of events to
effectively inhibit this interaction?
Dr. Boyle. This is an important distinction. As you point
out, a variety of different cytokines and other inflamma-
tory mediators are elevated in patients undergoing cardio-
pulmonary bypass, but in studying these different cyto-
kines in detail and trying to understand what they do, we
were drawn toward IL-8 because of its role in neutrophil
activation. Unlike inhibition of interleukin-1 or tumor
necrosis factor, which activate endothelial cells in a re-
dundant fashion, it seemed to us that inhibition of IL-8
might be beneficial.
Your second question, whether it is early or late enough
in the cascade, reflects an extremely delicate balance. As
I pointed out, some recent clinical and experimental
evidence suggests that if you wipe out the ability of the
neutrophil to attach to the endothelium, laboratory ani-
mals and patients in clinical studies may have an increased
incidence of infection. What we think is interesting about
this particular therapy is that the neutrophil should still
bind to the endothelium and should still respond to other
chemotactic factors. By targeting IL-8, we may be able to
reduce myocardial injury and apparently still allow some
of the other inflammatory functions to remain intact.
Dr. Fullerton. Do you think that you can dissociate the
injurious effect of the neutrophils from the immunologic,
protective effects of the neutrophils by using this [antibody
to IL-8] on a therapeutic basis?
Dr. Boyle. I think that the evidence we have provided
shows that by targeting IL-8 we can reduce the injurious
effects of myocardial reperfusion injury. Whether the
neutrophil will still function properly is unknown. There is
some evidence, for example, that knockout mice missing
the homolog of the IL-8 receptor do not have an increased
incidence of infection, unlike people with leukocyte adhe-
sion deficiency who are missing the neutrophil receptors
for CD11 and CD18. Perhaps inhibiting IL-8 may be a way
to reduce injury without significantly reducing the ability
to fight infection.
Dr. Fullerton. It is intuitively attractive, because obvi-
ously the neutrophil has been implicated in myocardial
infarction studies for some time but it has been a thera-
peutic obstacle to neutralize their effects. It is cumber-
some to perform neutrophil depletion in people or ani-
mals and it is potentially risky to completely block
neutrophil adhesive functions, so I think one of the things
that is particularly attractive about your line of investiga-
tion is that it might be able to dissociate the good from the
bad. One would like to preserve favorable neutrophil
function but prevent their bad effects. Could you speculate
on how you might use this strategy therapeutically? When
would you have to give this agent? You were able to give
it shortly before you reperfused your subjects, but if you
could speculate on a clinical basis, would you have to give
it in the preoperative medications?
Dr. Boyle. In our model we showed that we could
administer the antibody during ischemia, just before
reperfusion. This might be important, for example, as an
adjunct to thrombolysis in patients with evolving myocar-
dial infarctions. It would be nice to give this agent, as you
said, even before the patient is put to sleep. As you know,
one of the advantages of taking care of patients undergo-
ing cardiopulmonary bypass is that in many cases we can
give a drug like this before the operation, unlike in
cardiology or trauma, where one encounters a patient with
an ongoing event. The patient population we most com-
monly see in cardiothoracic surgery is thus ideally suited
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for therapies aimed at preventing the inflammatory aspect
of ischemia-reperfusion injury.
Dr. Vaughn A. Starnes (Los Angeles, Calif.). One of the
aspects that I was struck by was the amount of reperfusion
that you demonstrated in the two groups, the lack of
return to baseline of blood flow into the infarcted area.
We know that the size of an infarct is determined by
reperfusion injury, so one might suggest that you did not
get an increased infarct size because you did not reperfuse
it. Could you respond to this hypothesis?
Dr. Boyle. Yes, we calculated infarct size by counter-
staining with, in our case, Evans blue dye, with which one
can demarcate the area at risk, cut it away, and treat it
with 1% TTC. This stains the viable tissue red and the
nonviable tissue white, and these tissue amounts are
expressed as percentage weights to yield an estimate of
infarct size. In terms of your question about myocardial
blood flow, I think that this is one of the most interesting
aspects of this study. I was surprised to see that the
reduction in infarct size was independent of increased
recovery of blood flow. That raised a number of fascinat-
ing questions that we will be working out in a variety of
different ways in the laboratory. One mechanism is that
perhaps the neutrophils are still getting into the microvas-
culature and sticking to the activated endothelium, which
is mediated by other mechanisms such as the selectins and
the integrins, but are perhaps not becoming activated to
release the cytoplasmic granules that are so damaging. We
are going to use a variety of techniques to look at this in
the future, and it will be interesting to see how this all
turns out. In cardiothoracic surgery, as you know, we use
a lot of combinations of different drugs in cardioplegia to
try to achieve optimal myocardial protection. If it turns
out that antibody to IL-8 is beneficial in reducing neutro-
phil-mediated injury, it could be used in conjunction with
an agent that promotes blood flow, such as cyclic
guanosine monophosphate analogs or nitric oxide donors.
Dr. Aurelio Chaux (Los Angeles, Calif.). You showed us
some slides in which the number of neutrophils in the
tissues was apparently lower than the control value. Do
you have neutrophil counts for both control and treated
animals?
Dr. Boyle. This is a critical issue in this study. There
are a variety of different ways to quantify neutrophil
infiltration in tissue. One is to have a pathologist who is
unaware of the protocol individually count the neutro-
phils. As you saw, there were hundreds on the untreated
sections, making this approach difficult. We were rela-
tively convinced by the gross appearance, but we agree
with you that this assessment needs to be objectively
quantified. We are in the process of performing an
MPO assay in our laboratory. This should allow us to
put a number on the amount of MPO in both groups of
tissues, which in turn is directly related to neutrophil
infiltration. Unfortunately, this will not tell us whether
the neutrophils are activated; it will only yield a gross
estimate of their numbers. This is a critical issue that
deserves further attention.
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